I think the investor disappointment was more on the international performance in the second quarter for Humira than it was on Hep C.
As A Abbott Shareholder I would be disappointed if Abbott showed their hand before all the bids are in and the best offer is presented.
Mylan is buying PRGO, not Abt. Abt just happens to be the largest shareholder of Mylan and Abt agrees with Mylan's purchase of PRGO.
Investors should understand in detail a company's operating structures and how those structures can affect there P&L. Abbott is a highly diversified company with manufacturing, R&D and SG&A operations located in areas of point of sale. With geographical operation costs lined with geographical revenue there is a lot less impact due to currency fluctuation on the bottom line (EPS) along with good currency hedge programs.
If you are referring to the trailing 12 months PE's than you must adjust out the ABBV breakup fee for a comparison. Best to look at this year PE for both companies. Gilead 10, ABBV 12.
Your are right. The low information investors do not know the science behind Pharmacyclics and ABT199 and other drug combos. Nor do they understand the market entry strategy for these products. That is what happens when you are a short term thinker.
1.) Gives Abbv an infrastructure into oncology ie salesforce. 2.) Looks like the new drug has a lot of promise for more indications than the current 4. 3.) Potential fit for combo drugs that Abbv has in their pipeline of which some are in Phase III trials. 4.) Pharmacylics' pipeline. 5.) Acquired a proven effective research staff in the oncology field.
recombinantman, as far as why wineilli hangs around this board is so he can continue to whine. As far as the class action suit goes, these are nothing but ambulance chasers hoping to con some money for themselves. They come in droves whenever there is a M&A.
Depends on Current product growth and new indications plus what is in the pipeline and what other combinations drugs that Abbv has in the pipeline that my work with the new acquisitions products and pipeline. You may be right and you may be wrong but way too early to make statements like this.
That is why we elect board of directories. There is no time to wait around for stockholders to make up their minds and cast votes. Besides you can not show your hand when making deals.
As a stockholder, I am happy with $90 per share especially having Pfizer backing the deal. The only ones that will make out on all the law suits floating around are the ambulance chasing lawyers.
Humira, is taken for life and if a patient is doing ok on Humira a Doctor will think twice before prescribing a similar product. Also there are many other patents filed on humira just for the manufacturing and processing of the product. Also, Abbvie has been working on the next generation of this product.